Key Messages
This narrative review compiles evidence that has been generated during
the last 20 years on the use of pimecrolimus 1% cream in infants for
the treatment of atopic dermatitis. The authors believe this work is of
interest to the readers of Pediatric Immunology & Allergy, since use of
pimecrolimus is still restricted to children aged 2 years and above in
most countries, including European countries. According to the evidence
and the opinion of the authors there is currently no reason to support
this restriction any longer. The authors hope this review will convince
the readers to initiate treatment of atopic dermatitis already during
infancy and to consider topical pimecrolimus as an alternative to
topical corticosteroids for the treatment of atopic dermatitis in
infants aged 3 months and above.